Humoral and cellular immunogenicity and efficacy of a coxsackievirus A10 vaccine in mice

References

• Fang CY, Liu CC. Novel strategies for the development of hand, foot, and mouth disease vaccines and antiviral therapies. Expert Opin Drug Discov. 2022;17(1):27–39.
   PubMed Web of Science ®Google Scholar
• Min N, Ong YHB, Han AX, et al. An epidemiological surveillance of hand foot and mouth disease in paediatric patients and in community: a Singapore retrospective cohort study, 2013-2018. PLoS Negl Trop Dis. 2021;15(2):e0008885.
   PubMed Web of Science ®Google Scholar
• He XC, Zhang MM, Zhao C, et al. From monovalent to multivalent vaccines, the exploration for potential preventive strategies against hand, foot, and mouth disease (HFMD). Virol Sin. 2021;36(2):167–175.
   PubMed Web of Science ®Google Scholar
• Blomqvist S, Klemola P, Kaijalainen S, et al. Co-circulation of coxsackieviruses A6 and A10 in hand, foot and mouth disease outbreak in Finland. J Clin Virol. 2010;48(1):49–54.
   PubMed Web of Science ®Google Scholar
• Wu Y, Yeo A, Phoon MC, et al. The largest outbreak of hand foot and mouth disease in Singapore in 2008: the role of enterovirus 71 and coxsackievirus A strains. Int J Infect Dis. 2010;14(12):e1076–e1081.
   PubMed Web of Science ®Google Scholar
• Chen MY, He SZ, Yan Q, et al. Severe hand, foot and mouth disease associated with coxsackievirus A10 infections in Xiamen, China in 2015. J Clin Virol. 2017;93:20–24.
   PubMed Web of Science ®Google Scholar
• Meng XD, Tong YQ, Wei ZN, et al. Epidemical and etiological study on hand, foot and mouth disease following EV-A71 vaccination in Xiangyang, China. Sci Rep. 2020;10(1):20909.
   PubMed Web of Science ®Google Scholar
• Xie J, Yang XH, Hu SQ, et al. Co-circulation of coxsackieviruses A-6, A-10, and A-16 causes hand, foot, and mouth disease in Guangzhou city, China. BMC Infect Dis. 2020;20(1):271.
   PubMed Web of Science ®Google Scholar
• Fuschino ME, Lamson DM, Rush K, et al. Detection of coxsackievirus A10 in multiple tissues of a fatal infant sepsis case. J Clin Virol. 2012;53(3):259–261.
   PubMed Web of Science ®Google Scholar
• Lu QB, Zhang XA, Wo Y, et al. Circulation of coxsackievirus A10 and A6 in hand-foot-mouth disease in China, 2009-2011. PLoS One. 2012;7(12):e52073.
   PubMed Web of Science ®Google Scholar
• Zhou JY, Shi YY, Miao L, et al. Molecular epidemiology and recombination of enterovirus A71 in mainland China from 1987 to 2017. Int Microbiol. 2021;24(3):291–299.
   PubMed Web of Science ®Google Scholar
• Yi EJ, Shin YJ, Kim JH, et al. Enterovirus 71 infection and vaccines. Clin Exp Vaccine Res. 2017;6(1):4–14.
   PubMed Web of Science ®Google Scholar
• Zhang ZJ, Dong ZP, Li J, et al. Protective efficacies of formaldehyde-inactivated whole-virus vaccine and antivirals in a murine model of coxsackievirus A10 infection. J Virol. 2017;91(13):e00333–17.
   PubMed Web of Science ®Google Scholar
• Li SX, Zhao H, Yang LS, et al. A neonatal mouse model of coxsackievirus A10 infection for anti-viral evaluation. Antiviral Res. 2017;144:247–255.
   PubMed Web of Science ®Google Scholar
• Chen C, Xia Y, Zhu SR, et al. Muscle destruction caused by coxsackievirus A10 in gerbils: construction of a novel animal model for antiviral evaluation. Virus Res. 2020;286:198067.
   PubMed Web of Science ®Google Scholar
• Gao WJ, Yue L, Yang T, et al. Proliferation characteristics of coxsackievirus A10 in mice and immune protection ability of experimental inactivated vaccine. Biomed Pharmacother. 2021;143:112212.
   PubMed Web of Science ®Google Scholar
• Shen CY, Liu QW, Zhou Y, et al. Inactivated coxsackievirus A10 experimental vaccines protect mice against lethal viral challenge. Vaccine. 2016;34(41):5005–5012.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Zhang C, Liu QW, et al. A virus-like particle vaccine protects mice against coxsackievirus A10 lethal infection. Antiviral Res. 2018;152:124–130.
   PubMed Web of Science ®Google Scholar
• Zhang W, Dai WL, Zhang C, et al. A virus-like particle-based tetravalent vaccine for hand, foot, and mouth disease elicits broad and balanced protective immunity. Emerg Microbes Infect. 2018;7(1):94.
   PubMed Web of Science ®Google Scholar
• Deng HX, Yu S, Guo YZ, et al. Development of a multivalent enterovirus subunit vaccine based on immunoinformatic design principles for the prevention of HFMD. Vaccine. 2020;38(20):3671–3681.
   PubMed Web of Science ®Google Scholar
• Zhang ZJ, Dong ZP, Wang Q, et al. Characterization of an inactivated whole-virus bivalent vaccine that induces balanced protective immunity against coxsackievirus A6 and A10 in mice. Vaccine. 2018;36(46):7095–7104.
   PubMed Web of Science ®Google Scholar
• Duan SQ, Yang FM, Li YY, et al. Pathogenic analysis of coxsackievirus A10 in rhesus macaques. Virol Sin. 2022;37(4):610–618.
   PubMed Web of Science ®Google Scholar
• Standardization Administration of China. Laboratory animal guideline for ethical review of animal welfare. Beijing: Standardization Administration of China; 2018.
   Google Scholar
• Qian SS, Wei ZN, Jin WP, et al. Efficacy of a coxsackievirus A6 vaccine candidate in an actively immunized mouse model. Emerg Microbes Infect. 2021;10(1):763–773.
   PubMed Web of Science ®Google Scholar
• Reed LJ, Muench H. A simple method of estimating 50 percent end-points. Am J Epidemiol. 1938;27(3):493–497.
   Google Scholar
• Jin WP, Lu J, Zhang XY, et al. Efficacy of coxsackievirus A5 vaccine candidates in an actively immunized mouse model. J Virol. 2021;95:e01743–20.
   PubMed Web of Science ®Google Scholar
• Hu G, Jin WP, Yang ZH, et al. Efficacy of coxsackievirus A2 vaccine candidates correlating to humoral immunity in mice challenged with a mouse-adapted strain. Vaccine. 2022;40(33):4716–4725.
   PubMed Web of Science ®Google Scholar
• Khong WX, Yan B, Yeo HM, et al. A non-mouse-adapted enterovirus 71 (EV71) strain exhibits neurotropism, causing neurological manifestations in a novel mouse model of EV71 infection. J Virol. 2012;86(4):2121–2131.
   PubMed Web of Science ®Google Scholar
• Phillips BA, Fennell R. Polypeptide composition of poliovirions, naturally occurring empty capsids, and 14S precursor particles. J Virol. 1973;12(2):291–299.
   PubMed Web of Science ®Google Scholar
• Zhang ZJ, Dong ZP, Wei QJ, et al. A neonatal murine model of coxsackievirus A6 infection for evaluation of antiviral and vaccine efficacy. J Virol. 2017;91(9):e02450–16.
   PubMed Web of Science ®Google Scholar
• Zhang ZJ, Zhang XC, Carr MJ, et al. A neonatal murine model of coxsackievirus A4 infection for evaluation of vaccines and antiviral drugs. Emerg Microbes Infect. 2019;8(1):1445–1455.
   PubMed Web of Science ®Google Scholar
• Wang KT, Lin SJ, Wang HC, et al. Establishment of an animal challenge model as a potency assay for an inactivated enterovirus type 71 vaccine. Biologicals. 2016;44(4):183–190.
   PubMed Web of Science ®Google Scholar
• Ong KC, Devi S, Cardosa MJ, et al. Formaldehyde-inactivated whole-virus vaccine protects a murine model of enterovirus 71 encephalomyelitis against disease. J Virol. 2010;84(1):661–665.
   PubMed Web of Science ®Google Scholar
• Mao QY, Wang YP, Gao R, et al. A neonatal mouse model of coxsackievirus A16 for vaccine evaluation. J Virol. 2012;86(22):11967–11976.
   PubMed Web of Science ®Google Scholar
• Yin ZC, Wu YY, Zhu R, et al. Development of a neonatal mouse model for coxsackievirus B1 antiviral evaluation. Virol Sin. 2021;36(6):1575–1584.
   PubMed Web of Science ®Google Scholar
• Huang SW, Huang YH, Tsai HP, et al. A selective bottleneck shapes the evolutionary mutant spectra of enterovirus A71 during viral dissemination in humans. J Virol. 2017;91(23):e01062–17.
   PubMed Web of Science ®Google Scholar
• Ji WQ, Qin LW, Tao L, et al. Neonatal murine model of coxsackievirus A2 infection for the evaluation of antiviral therapeutics and vaccination. Front Microbiol. 2021;12:658093.
   PubMed Web of Science ®Google Scholar
• Ren R, Racaniello VR. Poliovirus spreads from muscle to the central nervous system by neutral pathways. J Infect Dis. 1992;166(4):747–752.
   PubMed Web of Science ®Google Scholar
• Jin PF, Li JX, Zhang XF, et al. Validation and evaluation of serological correlates of protection for inactivated enterovirus 71 vaccine in children aged 6-35 months. Hum Vaccin Immunother. 2016;12(4):916–921.
   PubMed Web of Science ®Google Scholar
• Zhu R, Cheng T, Yin ZC, et al. Serological survey of neutralizing antibodies to eight major enteroviruses among healthy population. Emerg Microbes Infect. 2018;7(1):2.
   PubMedGoogle Scholar
• Beck MA, Tracy SM. Murine cell-mediated immune response recognizes an enterovirus group-specific antigen(s). J Virol. 1989;63(10):4148–4156.
   PubMed Web of Science ®Google Scholar
• Kutubuddin M, Simons J, Chow M. Identification of T-helper epitopes in the VP1 capsid protein of poliovirus. J Virol. 1992;66(5):3042–3047.
   PubMed Web of Science ®Google Scholar
• Mahon BP, Katrak K, Mills KH. Antigenic sequences of poliovirus recognized by T cells: serotype-specific epitopes on VP1 and VP3 and cross-reactive epitopes on VP4 defined by using CD4+ T-cell clones. J Virol. 1992;66(12):7012–7020.
   PubMed Web of Science ®Google Scholar
• Foo DGW, Macary PA, Alonso S, et al. Identification of human CD4 T-cell epitopes on the VP1 capsid protein of enterovirus 71. Viral Immunol. 2008;21(2):215–224.
   PubMed Web of Science ®Google Scholar
• Wei RC, Yang CF, Zeng M, et al. A dominant EV71-specific CD4+ T cell epitope is highly conserved among human enteroviruses. PLoS One. 2012;7(12):e51957.
   PubMed Web of Science ®Google Scholar
• Tan SG, Tian XG, Sun XM, et al. VP2 dominated CD4+ T cell responses against enterovirus 71 and cross-reactivity against coxsackievirus A16 and polioviruses in a healthy population. J Immunol. 2013;191(4):1637–1647.
   PubMed Web of Science ®Google Scholar
• Gomez-Perosanz M, Sanchez-Trincado JL, Fernandez-Arquero M, et al. Human rhinovirus-specific CD8 T cell responses target conserved and unusual epitopes. FASEB J. 2021;35(1):e21208.
   PubMed Web of Science ®Google Scholar